CompletedPhase 1ketamine
A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers
Sponsored by Biogen
NCT ID
NCT01749098
Target Enrollment
29 participants
Start Date
2012-12
Est. Completion
2014-02
About This Study
To assess if PF-04958242 can attenuate the ketamine-induced cognitive impairment in verbal learning and memory, episodic memory and spatial working memory in healthy volunteers.
Conditions Studied
Interventions
- •PF-04958242
- •Ketamine
- •Placebo
- •Ketamine
Eligibility
Sex:MALE
Age:21 Years - 45 Years
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria: * Healthy male subjects 21 - 45 years old. * Able to read and write English as primary language. * Subjects who are willing to comply with study procedures. Exclusion Criteria: * History of any substance abuse or dependence disorder meeting DSM-IV criteria and/or by SCID-NP within the past 12 months, with the exception of nicotine. * Known sensitivity to ketamine * Any history of DSM-IV Axis I psychiatric disorders, determined by SCID-NP interview or diagnoses in the view of the investigator.
Study Locations (2)
Pfizer Investigational Site
New Haven, Connecticut, United States
Pfizer Investigational Site
West Haven, Connecticut, United States